LWA
SRNE

Lenox Wealth Advisors’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

Lenox Wealth Advisors’s Portfolio SRNE Stock Details SRNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$5K Hold
2,500
– – ﹤0.01% 572
2021
Q4 		$12K Hold
2,500
– – ﹤0.01% 490
2021
Q3 		$19K Hold
2,500
– – ﹤0.01% 373
2021
Q2 		$24K Hold
2,500
– – ﹤0.01% 332
2021
Q1 		$21K Buy
2,500
+500
+25% +$5.28K ﹤0.01% 307
2020
Q4 		$14K Hold
2,000
– – ﹤0.01% 381
2020
Q3 		$22K Buy
2,000
+700
+54% +$6.41K ﹤0.01% 274
2020
Q2 		$8K Buy
+1,300
New +$4.98K ﹤0.01% 403

Other funds holding SRNE

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Rafferty Asset Management
Rafferty Asset Management New York $24.6B AUM 47.06% 1-Year Est. Return

Lenox Wealth Advisors's SRNE Position: Q1 2022 in Review

Lenox Wealth Advisors held its Sorrento Therapeutics, Inc. (SRNE) position steady in Q1 2022 at 2,500 shares worth $5K. The position accounts for ﹤0.01% of the portfolio, ranked #572.

Lenox Wealth Advisors first reported a position in SRNE in Q2 2020 and has held it in 8 quarters since. The position peaked at $24K in Q2 2021. 235 funds tracked by Wall St. Rank hold SRNE as of Q1 2022.

  • Lenox Wealth Advisors held 2,500 shares of Sorrento Therapeutics, Inc. worth $5K as of Q1 2022.
  • Lenox Wealth Advisors left its Sorrento Therapeutics, Inc. share count unchanged in Q1 2022.
  • Sorrento Therapeutics, Inc. made up ﹤0.01% of Lenox Wealth Advisors's portfolio in Q1 2022, its #572 holding.
  • Lenox Wealth Advisors first reported a position in Sorrento Therapeutics, Inc. in Q2 2020 and has held it in 8 quarters since.
  • Lenox Wealth Advisors's Sorrento Therapeutics, Inc. position peaked at $24K in Q2 2021.
  • 235 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q1 2022.

Based on Lenox Wealth Advisors's 13F filing for Q1 2022, filed 14 Apr 2022.